Product Overview
[Drug Name]
Generic Name: Acipimox Capsules
Trade Name: HORAE Acipimox Capsules 0.25g x 16 capsules
[Main Ingredient]
Acipimox. Chemical Name: 5-Methylpyrazine-2-carboxylic acid-4-oxide. Molecular Formula: C6H6N2O3. Molecular Weight: 154.13
[Properties]
This product is a hard capsule containing white or off-white granules.
[Indications/Main Functions]
This product is used to treat hypertriglyceridemia (type IV), hypercholesterolemia (type Ia), and combined hypertriglyceridemia and hypercholesterolemia (type Ib).
[Specifications]
0.25g x 16 capsules
[Dosage and Administration]
The recommended dose is one capsule two to three times daily, taken with or after meals. The lower dose is used for type IV hypertriglyceridemia, while the higher dose is used for types Ia and Ib hypercholesterolemia. Improvement in blood lipid profiles is generally seen within one month of treatment. International literature reports that a safe daily dose of up to 1200 mg is safe for long-term use.
[Adverse Reactions]
This drug may cause skin vasodilation and increased heat sensitivity, such as facial hot flashes or pruritus, in the initial stages of treatment. These symptoms usually resolve within a few days of treatment and do not require discontinuation. Moderate gastrointestinal reactions (heartburn, upper abdominal pain, nausea, diarrhea, dry eyes, and urticaria) and headaches have occasionally been reported. In rare cases, patients experience local or systemic allergic reactions (such as rash, urticaria, maculopapular rash, lip edema, asthma-like dyspnea, and hypotension). Immediately discontinue the drug and seek symptomatic treatment.
[Contraindications]
This drug is contraindicated in patients with allergies or peptic ulcers, pregnant women, lactating women, and children.
[Drug Interactions]
This study has not been conducted and no references are available.
[Precautions]
1. Before using this drug, patients should adopt a low-cholesterol and low-fat diet and stop excessive alcohol consumption.
2. For patients with renal insufficiency, reduce the dose based on creatinine clearance data: For creatinine clearance (ml/min): 60-30 mg twice daily, 150 mg each time; 30-10 mg once daily, 150 mg each time; <10 mg once every other day, 150 mg each time.
3. Concomitant administration of cholestyramine will not affect the absorption of this product.
4. For patients requiring long-term use of this product, regular lipid and liver and kidney function tests should be performed.
[Pediatric Use]
This product is contraindicated in children.
[Elderly Use]
This study has not been conducted and no references are available.
[Overdose]
If overdose toxicity is observed, monitoring and systemic supportive care should be administered.
[Pharmacology and Toxicology]
Acipimox is a niacin derivative that inhibits the breakdown of adipose tissue and reduces the release of free fatty acids from adipose tissue, thereby decreasing triglyceride (TG) synthesis in the liver. By inhibiting the synthesis of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), it reduces blood triglyceride (TG) and total cholesterol (TC) concentrations. It also inhibits hepatic lipase activity and reduces the breakdown of high-density lipoprotein (HDL).
